Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells

Journal of Proteome Research

Volumn 8, Issue 6, 2009, Pages 3006-3019

  Ge, Feng ^a   Lu, Xin Peng ^a   Zeng, Hui Lan ^a   He, Quan Yuan ^b   Xiong, Sheng ^a   Jin, Lin ^a   He, Qing Yu ^a  

^a JINAN UNIVERSITY   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

Author keywords

14 3 3 ; Arsenic trioxide; Heat shock proteins; Multiple myeloma; Proteomics

Indexed keywords

ARSENIC TRIOXIDE; HEAT SHOCK PROTEIN 90; PROTEASOME; SMALL INTERFERING RNA; STRATIFIN; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RNA INTERFERENCE;

14-3-3 PROTEINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE KNOCKDOWN TECHNIQUES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MULTIPLE MYELOMA; OXIDES; PROTEIN INTERACTION MAPPING; PROTEOME; PROTEOMICS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRESS, PHYSIOLOGICAL; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 67049115481     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr9001004     Document Type: Article

References (44)

1. Kyle, R. A.; Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 2004, 351, 1860-1873.
2. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J. Cancer statistics. CA Cancer J. Clin. 2006, 56, 106-130.
3. Yang, L.; Parkin, D. M.; Ferlay, J.; Li, L.; Chen, Y. Estimates of Cancer Incidence in China for 2000 and Projections for 2005. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 243-250.
4. Kyle, R. A.; Rajkumar, S. V. Multiple myeloma. Blood 2008, 15, 2962-2972.
5. Soignet, S. L.; Maslak, P.; Wang, Z. G.; Jhanwar, S.; Calleja, E.; Dardashti, L. J.; Corso, D.; DeBlasio, A.; Gabrilove, J.; Scheinberg, D. A.; Pandolfi, P. P.; Warrell, R. P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998, 339, 1341-1348. (Pubitemid 28509343)
6. Perkins, C.; Kim, C. N.; Fang, G.; Bhalla, K. N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL. Blood 2000, 95, 1014-1022. (Pubitemid 30062726)
7. Zhang, T. C.; Cao, E. H.; Li, J. F.; Ma, W.; Qin, J. F. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur. J. Cancer 1999, 35, 1258-1263. (Pubitemid 29359187)
8. Ora, I.; Bondesson, L.; Jönsson, C.; Ljungberg, J.; Pörn-Ares, I.; Garwicz, S.; Pâhlman, S. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem. Biophys. Res. Commun. 2000, 277, 179-185. (Pubitemid 30796358)
9. Rousselot, P.; Labaume, S.; Marolleau, J. P.; Larghero, J.; Noguera, M. H.; Brouet, J. C.; Fermand, J. P. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 1999, 59, 1041-1048. (Pubitemid 29135964)
10. Park, W. H.; Seol, J. G.; Kim, E. S.; Hyun, J. M.; Jung, C. W.; Lee, C. C.; Kim, B. K.; Lee, Y. Y. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000, 60, 3065-3071. (Pubitemid 30395836)
11. Kajiguchi, T.; Yamamoto, K.; Iida, S.; Ueda, R.; Emi, N.; Naoe, T. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci. 2006, 97, 540-545. (Pubitemid 43811597)
12. Munshi, N. C.; Tricot, G.; Desikan, R.; Badros, A.; Zangari, M.; Toor, A.; Morris, C.; Anaissie, E.; Barlogie, B. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002, 16, 1835-1837. (Pubitemid 35050115)
13. Hussein, M. A.; Saleh, M.; Ravandi, F.; Mason, J.; Rifkin, R. M.; Ellison, R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br. J. Hamaetol. 2004, 125, 470-476. (Pubitemid 38916192)
14. Bahlis, N. J.; McCafferty-Grad, J.; Jordan-McMurry, I.; Neil, J.; Reis, I.; Kharfan-Dabaja, M.; Eckman, J.; Goodman, M.; Fernandez, H. F.; Boise, L. H.; Lee, K. P. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res. 2002, 8, 3658-3668. (Pubitemid 35424755)
15. Kurki, S.; Latonen, L.; Laiho, M. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J. Cell Sci. 2003, 116, 3917-3925. (Pubitemid 37279307)
16. Lallemand-Breitenbach, V.; Zhu, J.; Puvion, F.; Koken, M.; Honoré, N.; Doubeikovsky, A.; Duprez, E.; Pandolfi, P. P.; Puvion, E.; Freemont, P.; de Thé, H. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 2001, 193, 1361-1371. (Pubitemid 32565965)
17. Mathas, S.; Lietz, A.; Janz, M.; Hinz, M.; Jundt, F.; Scheidereit, C.; Bommert, K.; Dorken, B. Inhibition of NF-kB essentially contributes to arsenic-induced apoptosis. Blood 2003, 102, 1028-1034. (Pubitemid 36917800)
18. Lin, D. Y.; Lai, M. Z.; Ann, D. K.; Shih, H. M. Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor coactivator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential. J. Biol. Chem. 2003, 278, 15958-15965. (Pubitemid 36799714)
19. Verma, A.; Mohindru, M.; Deb, D. K.; Sassano, A.; Kambhampati, S.; Ravandi, F.; Minucci, S.; Kalvakolanu, D. V.; Platanias, L. C. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J. Biol. Chem. 2002, 277, 44988-44995. (Pubitemid 36159097)
20. Wang, Y.; He, Q. Y.; Sun, R. W.; Che, C. M.; Chiu, J. F. GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species. Cancer Res. 2005, 15, 11553-11564. (Pubitemid 41821714)
21. Wang, Y.; Cheung, Y. H.; Yang, Z.; Chiu, J. F.; Che, C. M.; He, Q. Y. Proteomic approach to study the cytotoxicity of dioscin (saponin). Proteomics 2006, 6, 2422-2432.
22. Wang, Y.; Chiu, J. F.; He, Q. Y. Proteomics approach to illustrate drug action mechanisms. Curr. Drug Discov. Technol. 2006, 3, 199-209. (Pubitemid 46425956)
23. Wang, Y.; He, Q. Y.; Che, C. M.; Tsao, S. W.; Sun, R. W.; Chiu, J. F. Modulation of gold(III) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways. Biochem. Pharmacol. 2008, 15, 1282-1291.
24. Lei, T.; He, Q. Y.; Cai, Z.; Zhou, Y.; Wang, Y. L.; Si, L. S.; Cai, Z.; Chiu, J. F. Proteomic analysis of chromium cytotoxicity in cultured rat lung epithelial cells. Proteomics 2008, 8, 2420-2429.
25. Karasavvas, N.; Cárcamo, J. M.; Stratis, G.; Golde, D. W. Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood 2005, 105, 4004-4012. (Pubitemid 40656149)
26. Thomas, P. D.; Campbell, M. J.; Kejariwal, A.; Mi, H.; Karlak, B.; Daverman, R.; Diemer, K.; Muruganujan, A.; Narechania, A. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003, 13, 2129-2141. (Pubitemid 37161770)
27. Mi, H.; Guo, N.; Kejariwal, A.; Thomas, P. D. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res. 2007, 35, D247-D252. (Pubitemid 46056208)
28. von Mering, C.; Jensen, L. J.; Snel, B.; Hooper, S. D.; Krupp, M.; Foglierini, M.; Jouffre, N.; Huynen, M. A.; Bork, P. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res. 2005, 33, D433-D437. (Pubitemid 40207910)
29. von Mering, C.; Jensen, L. J.; Kuhn, M.; Chaffron, S.; Doerks, T.; Krüger, B.; Snel, B.; Bork, P. STRING 7 - recent developments in the integration and prediction of protein interactions. Nucleic Acids Res. 2007, 35, D358-D362. (Pubitemid 46056231)
30. Giles, R. V.; Grzybowski, J.; Spiller, D. G.; Tidd, D. M. Enhanced antisense effects resulting from an improved streptolysin-o protocol for oligodeoxynucleotide delivery into human leukaemia cells. Nucleosides Nucleotides 1997, 16, 1155-1163. (Pubitemid 27494443)
31. Giles, R. V.; Spiller, D. G.; Grzybowski, J.; Clark, R. E.; Nicklin, P.; Tidd, D. M. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. Nucleic Acids Res. 1998, 26, 1567-1575. (Pubitemid 28291789)
32. Brito, J. L.; Davies, F. E.; Gonzalez, D.; Morgan, G. J. Streptolysin-O reversible permeabilisation is an effective method to transfect siRNAs into myeloma cells. J. Immunol. Methods 2008, 333, 147-155.
33. Wang, Z. G.; Rivi, R.; Delva, L.; König, A.; Scheinberg, D. A.; Passerini, C. G.; Gabrilove, J.; Larrell, R. P.; Pandolfi, P. P. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARa independent manner. Blood 1998, 92, 1497-1504. (Pubitemid 28406851)
34. Akao, Y.; Mizoguchi, H.; Kojima, S.; Naoe, T.; Ohishi, N.; Yagi, K. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br. J. Hamaetol. 1998, 102, 1055-1060. (Pubitemid 28410539)
35. Zhang, W.; Ohnishi, K.; Shigeno, K.; Fugisawa, S.; Naito, K.; Nakamura, S.; Takeshita, K.; Takeshita, A.; Ohno, R. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998, 12, 1383-1391. (Pubitemid 28442384)
36. Fu, H.; Subramanian, R. R.; Masters, S. C. 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 617-647. (Pubitemid 30340695)
37. Aitken, A. 14-3-3 proteins: A historic overview. Semin. Cancer. Biol. 2006, 16, 162-172. (Pubitemid 43796128)
38. Niemantsverdriet, M.; Wagner, K.; Visser, M.; Backendorf, C. Cellular functions of 14-3-3zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 2008, 27, 1315-1319. (Pubitemid 351294692)
39. Li, Z.; Zhao, J.; Du, Y.; Park, H. R.; Sun, S. Y.; Bernal-Mizrachi, L.; Aitken, A.; Khuri, F. R.; Fu, H. Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 162-167.
40. Luo, G. R.; Chen, S.; Le, W. D. Are heat shock proteins therapeutic target for Parkinson's disease. Int. J. Biol. Sci. 2007, 3, 20-26. (Pubitemid 46155761)
41. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Fanourakis, G.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T. A.; Treon, S. P.; Munshi, N. C.; Richardson, P. G.; Hideshima, T.; Anderson, K. C. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 14374-14379. (Pubitemid 35257679)
42. Catley, L.; Weisberg, E.; Kiziltepe, T.; Tai, Y. T.; Hideshima, T.; Neri, P.; Tassone, P.; Atadja, P.; Chauhan, D.; Munshi, N. C.; Anderson, K. C. Aggresome induction by proteasome inhibitor bortezomib and tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108, 3441-3449. (Pubitemid 44776885)
43. Kim, D.; Kim, S. H.; Li, G. C. Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression. Biochem. Biophys. Res. Commun. 1999, 254, 264-268. (Pubitemid 29292051)
44. Mitsiades, C. S.; Mitsiades, N. S.; McMullan, C. J.; Poulaki, V.; Kung, A. L.; Davies, F. E.; Morgan, G.; Akiyama, M.; Shringarpure, R.; Munshi, N. C.; Richardson, P. G.; Hideshima, T,; Chauhan, D.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T. A.; Rosen, N. S.; Anderson, K. C. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006, 107, 1092-1100. (Pubitemid 43156310)